ALK G1202R: the solvent-front mutation that resets the ladder

ALK-rearranged NSCLC has the deepest targeted-therapy bench in lung cancer — five approved inhibitors across three generations. But progression is the rule, not the exception, and one mutation does more damage than any other. ALK G1202R sits in the solvent-front region of the kinase, and a single glycine→arginine swap is enough to knock out four of the five approved drugs at once. Here’s why it happens, why lorlatinib is the exception, and what the resistance landscape looks like once lorlatinib fails too.

What G1202R actually does

Residue 1202 sits at the edge of the ATP pocket, in the solvent-exposed strip medicinal chemists call the “solvent front.” Glycine has no side chain at all. Arginine has a long, flexible, positively charged one. Drop that side chain into the solvent front and it sterically clashes with the part of an inhibitor that pokes out toward solvent — the part most ALK drugs were never designed to tuck away.

Gainor et al. (2016) sequenced 103 repeat biopsies from ALK-positive patients progressing on ALK inhibitors. G1202R was rare after crizotinib but became the single most common on-target resistance mechanism after second-generation agents, accounting for roughly half of the on-target resistance seen with ceritinib, alectinib, and brigatinib. It is, quite specifically, the mutation those drugs select for.

The five-drug ladder

• Crizotinib (Xalkori) — Pfizer, FDA approved 2011. First-in-class, originally developed as a MET inhibitor. Modest CNS penetration, so the brain is a common first site of progression.
• Ceritinib (Zykadia) — Novartis, 2014. Second generation, more potent than crizotinib and active against several crizotinib-resistance mutations — but not G1202R.
• Alectinib (Alecensa) — Roche, 2015. Second generation with strong CNS penetration; became a first-line standard. Does not cover G1202R.
• Brigatinib (Alunbrig) — Takeda, 2017. Second generation with the broadest mutation coverage of the group, yet G1202R still escapes it.
• Lorlatinib (Lorbrena) — Pfizer, 2018. Third generation, macrocyclic, with a purpose-built compact scaffold and high CNS penetration. The one drug on this list that covers G1202R.

Why lorlatinib survives the solvent front

Lorlatinib was designed as a macrocycle: the molecule is cyclized, which makes it rigid and compact. A compact inhibitor presents less surface to the solvent front, so the bulky arginine side chain of G1202R has less to clash with. That structural bet paid off in the clinic. In the CROWN trial of first-line lorlatinib versus crizotinib, the 5-year update (Solomon et al., 2024) reported 5-year progression-free survival of 60% with lorlatinib versus 8% with crizotinib, with median PFS still not reached after five years of follow-up — the longest PFS reported for any single-agent targeted therapy in advanced NSCLC. Intracranial control was just as lopsided.

What comes after lorlatinib: compound mutations

Lorlatinib is broad, but it is not bottomless. When it fails, the resistance mechanism is usually a compound mutation: G1202R plus a second ALK mutation in cis, on the same allele. Yoda et al. (2018) showed that sequential use of ALK inhibitors actively selects for these lorlatinib-resistant compound mutations — G1202R/L1196M, C1156Y/L1198F, G1202R/S1206Y, and others — with roughly a third of patients treated through a full sequence of ALK inhibitors eventually developing them.

That is the clinical lesson baked into CROWN. Leading with lorlatinib first-line, rather than climbing the ladder one rung at a time, may sidestep the sequential selection pressure that builds compound mutations in the first place. Fourth-generation ALK inhibitors aimed squarely at the compound-mutant kinase are in development, but for now the cleanest move against G1202R is to not give it the runway.

Try the docking yourself

The solvent-front clash is something you can see directly. Open Studio and pick ALK from the target catalog with G1202R from the mutation chips. Liganx renders the wild-type and G1202R receptors side by side, so you can watch the arginine side chain crowd the solvent-front edge of the pocket. Dock a compact, macrocycle-like ligand and a bulkier extended one against both: the compact ligand should hold its score against the mutant while the extended one loses a kcal/mol or two. That ΔΔ between wild-type and mutant is the selectivity story, and it is the number that matters more than either absolute score.

Liganx is molecular docking online: a free, browser-based platform with no install and no local GPU required. It is a fast way to put molecular docking to work on a resistance question like G1202R and watch the wild-type-versus-mutant story for yourself.

Primary sources

• Gainor JF, et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov 6, 1118–1133 (2016). doi:10.1158/2159-8290.CD-16-0596
• Yoda S, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov 8, 714–729 (2018). PMC5984716
• Solomon BJ, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol 42, 3400–3409 (2024). doi:10.1200/JCO.24.00581